Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antimicrobial Self-Stewardship: Putting the CDCs antibiotic “timeouts” to work Todd C. Lee MD MPH FRCPC Internal Medicine and Infectious Diseases McGill.

Similar presentations


Presentation on theme: "Antimicrobial Self-Stewardship: Putting the CDCs antibiotic “timeouts” to work Todd C. Lee MD MPH FRCPC Internal Medicine and Infectious Diseases McGill."— Presentation transcript:

1 Antimicrobial Self-Stewardship: Putting the CDCs antibiotic “timeouts” to work Todd C. Lee MD MPH FRCPC Internal Medicine and Infectious Diseases McGill University Health Centre (Royal Victoria Hospital / Montreal General Hospital) Assistant Professor of Medicine, McGill University

2 What is Stewardship? Optimizing: – Selection of spectrum – Dose – Route – Duration To MAXIMIZE clinical cure or prevention of infection

3 While reducing: 1.Adverse drug events (including C. difficile) 2.Antimicrobial resistance within the hospital 3.Cost

4 While reducing: 1.Adverse drug events (including C. difficile) 2.Antimicrobial resistance within the hospital 3.Cost

5

6

7 While reducing: 1.Adverse drug events (including C. difficile) 2.Antimicrobial resistance within the hospital 3.Cost

8

9 While reducing: 1.Adverse drug events (including C. difficile) 2.Antimicrobial resistance within the hospital 3.Cost

10 Methods of Stewardship Guidelines/Education Formulary restriction – Often using special forms Antibiotic rotation – i.e. change the common antibiotics used for certain infections periodically Prospective audit and feedback

11 Guidelines Attempt to synthesize evidence-based recommendations based on local epidemiology Goal is to eliminate variability in practice for the most common infections Recommendations based on epidemiology and principles of stewardship

12 Local guidelines Consensus amongst ID faculty Based on professional society guidelines Adapted to base on local epidemiology/resistance patterns Adjusted for new publications within the field Revised annually since 2011

13 Community Acquired Pneumonia What are the common pathogens? Which antibiotics predictably cover them in your community? Which antibiotics do we favor locally? Does the patient have an epidemiologic risk for an infection not usually covered?

14 Community Acquired Pneumonia Notes: PO quinolones or azithromycin as soon as tolerates oral In the absence of bacteremic Staphylococcus aureus, empyema, abscess, necrotizing lung infection or Legionella: CAP may safely be treated with FIVE days total therapy – particularly with fluoroquinolones for which RCT data is available and robust – Clin Infect Dis. (2011) 52 (10): 1232-1240

15 COPD Who should receive antibiotics (if you accept that they are associated with benefit)? What are the major pathogens? What is our local resistance? What is known about the patient’s own microbiology?

16 COPD Exacerbations = 2 of 3 of sputum, purulence, dyspnea; not pneumonia No risk factors for resistance: One of: FEV1<50; 4 exacerbations/yr., home O2, steroids recently, abx in past 3 months

17 Cellulitis Uncomplicated: – no venous catheter around site – no water borne injury or bite wound – non-neutropenic – not associated with purulence, gangrene, fasciitis or an infected diabetic foot ulcer **Up to 75% likely group A streptococcus and up to 95% will respond to narrow spectrum beta-lactams** Jeng et al., Medicine July 2010 - Volume 89 - Issue 4 - pp 217-226

18 Empiric MRSA Coverage Unless shock or purulence, empiric VANCOMYCIN not required unless clearly not responding to beta-lactam

19 Frequent use of potentially unnecessary diagnostic studies, broad-spectrum antibiotic therapy, and prolonged treatment courses in these patients suggest targets for antimicrobial stewardship programs.

20 The diabetic foot Mild: Moderate:

21 The diabetic foot LIMB THREATENING – i.e. vascular surgery probably should be the one admitting

22 C. Difficile – 1 st episode or 1 st relapse NB: 125mg VANCOMYCIN dose for moderate. Never been shown more is better – certainly costs more (especially when they go home!)

23 UTI The elephant is in the room!

24 UTI In general requires: – Positive urinalysis (unless neutropenic) + – Symptoms attributable to lower or upper urinary tract

25 Asymptomatic bacteriuria Very common – especially in female patients from nursing homes, incontinent patients Free guidelines available online from the IDSA – http://www.idsociety.org/uploadedFiles/IDSA/Guidelines- Patient_Care/PDF_Library/Asymptomatic%20Bacteriuria.pdf

26 Asymptomatic bacteriuria Treatment in adults should be limited to: – Pregnant women – Upcoming invasive urologic procedure TURP Procedure where there will be mucosal bleeding Doing a renal transplant

27 Asymptomatic bacteriuria Randomized trials have shown no harm in not treating – See also: Gross PA, Patel B Reducing antibiotic overuse: a call for a national performance measure for not treating asymptomatic bacteriuria. Clin Infect Dis 2007;45:1335- 1337.

28 Asymptomatic bacteriuria Other randomized trials have shown treating causes more resistance and paradoxically more UTIs – Clin Infect Dis. (2012) 55 (6): 771-777.

29 Asymptomatic bacteriuria Many will use in kidney transplant 1 st month Beyond 1 month some evidence of increased rate of symptomatic UTIs requiring hospitalization

30

31 NOTE: Excluded 1 st MONTH Cohort study – but similar effects seen in three other cohorts

32 Scope of the problem We performed 38048 urine cultures in 2012! Each urine culture costs $7.40 Total Cost (lab only) = $281 555 – Downstream costs exponentially more – Antibiotics (potentially IV) C. difficile, resistance, $$$ – Length of Stay

33

34 CULTURES WITHOUT INDICATION VERY COMMON INPATIENT CLINICAL YIELD EXTREMELY LOW (<2%) UNNECESSARY ANTIBIOTICS IN UP TO 50% RAISES THE QUESTION: DO THESE CULTURES DO MORE HARM THAN GOOD?

35

36

37 Take home message Avoid treating asymptomatic bacteriuria Avoid culturing urine looking for ASB without good reason

38 UTI – Hospitalized patients \ Gentamicin with caution in: – Renal insufficiency or concomitant administration of other nephrotoxins – Cirrhosis (hepatorenal syndrome) – Existing sensorineural hearing loss or vestibular dysfunction Level independent side effects – Existing sensory neuropathy for which loss of vestibular function would be severely disabling Make sure levels are done after 48 hours of use and that you consult with your pharmacist to ensure proper monitoring and targets Culture data is going to be important to find alternative agent for longer use

39 Your mission… For each of your patients, at regular intervals – Take a “time out” to reassess their antibiotics

40 Antibiotic Self-Stewardship Concept: – Periodic twice weekly scheduled review of all antibiotics by the practicing team – On demand involvement of ID

41 Advantages of self-stewardship! Maintain full control over antibiotic prescription without external influence Develop skills in antibiotic stewardship which are expected to have long term educational effects over a career

42 How do I perform self-stewardship? Then next several minutes dedicated to teaching our housestaff how to use the electronic audit tool properly. This tool is available for you to view in appendix 2

43

44 If the patient does not have a suspected or proven infection (i.e. you now know their hypotension was caused by a GI bleed and not sepsis) then it follows their empiric antibiotics should be stopped

45

46

47

48 Guidelines Compare the antibiotics the patient is receiving to those in the MUHC guidelines and the guidelines I presented If they aren’t on guideline approved antibiotics, why is that? – No guideline exists? – Culture data? – Allergy? – “Clinical judgment” to use alternative? In general it is best practice to follow your local guidelines

49 Microbiology Microbiology is essential to choosing the right antibiotics for the infection in question Timely review of all recent results leads to the most appropriate management

50 IV -> PO Many antibiotics are highly available PO (FQ, metronidazole, TMP/SMX) Many infections do not require parenteral antibiotics to achieve cure Change to PO, when appropriate, can reduce: – Need for IV access and associated complications – Length of stay – Cost

51

52

53 Duration Review the duration received and compare to what the guidelines, literature, clinical experience or consultants suggest Record the number of days received and compare against the number of planned days Stop today if it is time or set a stop date in the future to avoid inadvertent renewal or discontinuation

54

55 Targeted Drugs Review and optimize the use of targeted drugs In particular: – Minimizing FQ use may help reduce C. difficile – “PIP-TAZO” is the one of the most used antibiotics at our centre – Carbepenem use should be minimized as they are expensive and our last-resort drugs (keep KPC out!) – Vancomycin is also probably overused and potentially nephrotoxic requiring laboratory monitoring in patients without risk for MRSA or other organism

56

57

58

59 Audit Completed Thank you! Expected workload not greatly in excess of existing procedures – As little as 30 seconds per audit

60 Still don’t know what to do with the antibiotics? Ask your staff first Then if still in doubt: – Consult the Infectious Diseases Service – Page your self-stewardship advisor for advice (via locating) if you aren’t sure if you need a full consult or have any questions about the antibiotic timeout process.


Download ppt "Antimicrobial Self-Stewardship: Putting the CDCs antibiotic “timeouts” to work Todd C. Lee MD MPH FRCPC Internal Medicine and Infectious Diseases McGill."

Similar presentations


Ads by Google